anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A 12-week prospective study of two groups of adolescents (ages 10-18 years) with attention deficit/hyperactivity disorder (ADHD); 1) ADHD adolescents with a first degree relative with bipolar disorder ("high-risk") and 2) ADHD adolescents without any first or second degree-relatives with a mood disorder ("low-risk"). Patients will be evaluated using diagnostic interviews and symptom ratings, will receive neuroimaging scans (fMRI, DTI, 1H MRS), and will then be assigned to treatment. Low-risk ADHD adolescents (n=60) will receive treatment with open-label mixed amphetamine salts-extended release (MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD. High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). Following initiation of treatment, the ADHD adolescents will have regularly scheduled visits during which symptom and tolerability ratings will be performed. Healthy subjects (n=60) will be recruited from the community and will not receive medication but will undergo magnetic resonance imaging (MRI) scans at the same intervals to assess normal variability in imaging parameters between time points as well as to adjust and interpret comparisons within patients (i.e., whether patient values are changing toward or away from those of healthy adolescents). Neuroimaging (fMRI, DTI,1H MRS) evaluations will be performed at baseline and Week 12 (or termination).
Belonging to the field of medical technologies, the invention in particular relates to a pharmaceutical composition of empagliflozin and metformin, a preparation method and application thereof. The composition comprises the following components: i.) empagliflozin; ii.) metformin hydrochloride; and one or more fillers; one or more adhesives; one or more flow aids and one or more lubricants. Specifically, the empagliflozin has less than 200micrometer particle size distribution, and can be made into tablets. The composition has the unexpected and especially advantageous properties, thus being suitable for patients of type II diabetes, and being applicable to improvement of blood glucose control and treatment and/or prevention of metabolic diseases (including slowing down their progress or delaying their attack), especially diabetes (in particular type II diabetes) and related diseases (like diabetic complication).
The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms (A sociodemographic questionnaire, Genital Hygiene Behavior Inventory (GHBI), and Self-Care Agency Scale (SCAS). The post-test forms (GHBI, SCAS) were re-administered 4 weeks later to women who did not receive any intervention.
Adults with spinal cord injury (SCI) demonstrate accelerated atherosclerotic cardiovascular disease (ASCVD) occurring \~4 fold more often, and decades earlier in life. Importantly, atherosclerosis has been detected in people with SCI independent of traditional risk factors, much earlier in life, and appear recalcitrant to conventional risk mitigating inventions such as exercise and diet. Also, as disease is silent, many individuals are not screened for this atherosclerotic burden and only aware after the major vascular event of a myocardial infarction or stroke. The mechanisms which drive early ASCVD is unknown. Endothelial cell dysfunction precedes radiographic or angiographic evidence of atherosclerosis, and plays a central role in the development, progression and severity of atherosclerotic vascular disease. While it has been suggested that SCI results in compromised endothelial health, there is little empirical data on the degree or scope of impairment as well as mechanisms underlying any potential impairment. Endothelial dysfunction may be an important factor underlying the increased risk and prevalence of ASCVD and associated events in adults with SCI and a viable target for therapeutic intervention. Preliminary data suggests primary endothelial cell impairment related to its vasodilator function and provide potential mechanisms related to oxidative stress burden. The investigators also present the potential of endothelial cell derived microvesicles as a biomarker and mediator of endothelial cell dysfunction. The aim of this proposal is to determine whether endothelial function is impaired in adults with SCI. Our hypothesis is that endothelium-dependent vasodilation is impaired in adults with SCI and oxidative stress and endothelial cell derived microvesicles contribute to this dysfunction. Results supporting this hypothesis will: 1) provide mechanistic insight into the excess risk of ASCVD in adults with SCI; 2) identify therapeutic targets for reducing cardiovascular risk in this population; and 3) provide scientific rationale for vascular-related treatment clinical trials aimed at improving vascular health and reducing cardiovascular risk in individuals with SCI.
The invention relates to application of a novel phenolic acid compound in preparing an antioxidant medicine, and also relates to a preparation method for extracting, separating and purifying the compound from a traditional Chinese medicine caulis sinomenii. The preparation method is simple and feasible, and the obtained compound has high purity. Pharmacological research shows that the new compound has better capacity of eliminating free radicals in vitro and can reduce H 2 O 2 Induced generation of Reactive Oxygen Species (ROS) within macrophage RAW 264.7. In addition, the activity of intracellular superoxide dismutase (SOD) can be increased. Show thatThe compound of the invention has obvious antioxidant activity and can be used for preparing antioxidant drugs. Has good economic benefit and application prospect.
In susceptible individuals, isoflurane anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. The syndrome includes nonspecific features such as muscle rigidity, tachycardia, tachypnea, cyanosis, arrhythmias and unstable blood pressure. (It should also be noted that many of these nonspecific signs may appear with light anesthesia, acute hypoxia, etc.) An increase in overall metabolism may be reflected in an elevated temperature (which may rise rapidly early or late in the case, but usually is not the first sign of augmented metabolism) and an increased usage of the CO2 absorption system (hot cannister). PaO2 and pH may decrease, and hyperkalemia and a base deficit may appear. Treatment includes discontinuance of triggering agents (e.g., isoflurane), administration of intravenous dantrolene sodium, and application of supportive therapy. Such therapy includes vigorous efforts to restore body temperature to normal, respiratory and circulatory support as indicated, and management of electrolyte- fluid-acid-base derangements. (Consult prescribing information for dantrolene sodium intravenous for additional information on patient management). Renal failure may appear later, and urine flow should be sustained if possible.

Since levels of anesthesia may be altered easily and rapidly, only vaporizers producing predictable concentrations should be used Hypotension and respiratory depression increase as anesthesia is deepened.

Increased blood loss comparable to that seen with halothane has been observed in patients undergoing abortions.

Isoflurane markedly increases cerebral blood flow at deeper levels of anesthesia. There may be a transient rise in cerebral spinal fluid pressure which is fully reversible with hyperventilation.
PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
PURPOSE: The aim of this study was to examine the postoperative outcomes and follow-up QOL of patients after AWR at a level-1 trauma centre in India.
METHODS: The study cohort included AWR patients treated between January 2011 and July 2022. The Activities Assessment Scale (AAS) was used to measure QOL, and the Ventral Hernia Recurrence Inventory (VHRI) was used to determine the occurrence of recurrence. In patients suspected of having recurrence, thorough clinical examination and relevant imaging were performed to confirm or rule out recurrence.
RESULTS: Out of 89 patients, 35 patients whose complete perioperative and follow-up data were available were enrolled. The mean age of the patients was 28 (SD, 9) years. The mean defect size was 14. 9 (SD, 7) cm. The mean time from laparotomy to AWR surgery was 21 months. During the postoperative course, 37% of patients developed complications, such as SSI and seroma. The mean follow-up time was 53 (SD, 43) months. Upon comparing procedures involving the mesh placed in the sublay position with procedures involving the mesh placed in other positions, no statistically significant difference in the recurrence rate (one in each group, p = 0.99), surgical complication rate (33% v/s 66%, p = 0.6), or mean AAS QOL score (94.7 v/s 98, p = 0.4) was observed. The specificity of the VHRI for diagnosing recurrence was 79%.
CONCLUSION: Overall, the recurrence rate was low in these patients despite the presence of large hernia defects. Long-term QOL was not affected by the specific procedure used. Timely planning and execution are more important than the specific repair approach for post-trauma laparotomy ventral hernia.
Platelet-rich plasma (PRP) is used to treat dural leaks. In the preferred embodiment, a mixture of calcium chloride and thrombin is added to release valuable components such as soluble regulators and growth factors. The growth factors in particular may also help expedite healing of the dura. The PRP may be combined with calcium and/or thrombin before during, or after injection of the PRP. The PRP may be injected into the epidural space through a spinal needle to treat dural leaks. Syringe attachments that allow two liquids to combine at the time of injection are readily available in hospitals.
Women in the Healthy Lifestyle group will be invited to attend the online NDPP-NextGen class which will cover how to eat healthy, be active, and lose weight before getting pregnant. The classes will be led by a trained Lifestyle Coach. Each class lasts about 1 hour. Classes initially meet about once a week (for the first 6 months), then twice a month (for the next 3 months), and then once a month (for the last 3 months). Classes will meet virtually through video-conference. Lifestyle coaches will also call participants in between classes to discuss how participants are doing, answer questions, and provide reminders for upcoming classes. Prior to the first class, women will also participate in a "pre-session" designed to increase NDPP engagement via discussion of diabetes risks and treatment options (i.e., clarify relevance) and motivational interviewing to resolve barriers.
The cardiac hormone brain natriuretic peptide (BNP) plays an important role in the pathophysiology of congestive heart failure (CHF). Studies have established that BNP mediates natriuresis, renin and aldosterone (RAAS) inhibition, vasodilation and lusitropism. Acute cardiac hormone replacement with intravenous infusion of BNP has been shown to possess potent vasodilating actions in humans with acute decompensated CHF resulting in improvement of clinical symptoms. Natrecor (nesiritide) a sterile, purified preparation of human BNP is approved by the FDA for intravenous administration in the treatment of patients with acute decompensated congestive heart failure. However, chronic cardiac hormone replacement with BNP as therapeutic strategy in CHF has been limited by the need to administer BNP intravenously. The objective of this study is to define the cardiorenal and humoral actions of short term (eight weeks) chronic cardiac hormone replacement with subcutaneous (SQ) BNP in human NYHA class II-III CHF. Systolic and diastolic function, left ventricular remodeling as assessed by its volume, renal function, neurohumoral profiling and exercise capacity will be assessed prior to and after eight weeks of treatment.
During the first-pass colonoscopy, the procedure was performed in the usual fashion, with minimal CO2 insufflation to aid insertion. Cleaning of colon was predominantly performed during withdrawal. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
<P>PROBLEM TO BE SOLVED: To provide a physiologically active complex exhibiting improved pharmacokinetics and having a tumor necrosis factor activity.  <P>SOLUTION: This physiologically active complex comprises a protein portion having a tumor necrosis factor activity and a polymer portion artificially bound to the N-terminal of the protein. The physiologically active complex is stable, has a significantly long retention time in a living body, and retains an initial level in blood for a long time, even when administered at a low dose, in comparison with a physiologically active substance not having the polymer portion. Namely, the physiologically active complex comprises the protein portion having the tumor necrosis factor activity and the polymer portion comprising a polyethylene glycol homopolymer or copolymer or its derivative and artificially bound to the N-terminal of the protein. A sensitive disease medicine contains the physiologically active complex as an active ingredient.  <P>COPYRIGHT: (C)2004,JPO
A polypeptide and an application thereof in manufacturing a pharmaceutical product for treating and/or preventing a tumor. The amino acid sequence of the polypeptide is represented by SEQ ID No. 1. Alternatively, two or more amino acids within the amino acid sequence represented by the SEQ ID No. 1 can be replaced with an unnatural amino acid with a linkable side chain. The polypeptide or polypeptide derivative can achieve targeted increase of the quantity of a PML nuclear body, and can therefore be applied in a manufacturing of a pharmaceutical product for treating and/or preventing a tumor.
Psychosocial interventions, especially supportive-expressive group therapies, have been associated with significant improvements in health status, quality of life and coping behaviors, in patients with cancer. The purpose of the proposed pilot research study is to investigate a newly developed group therapy for cancer patients, MBAT. This proposed, randomized, controlled study follows a successful preliminary investigation of MBAT conducted at Thomas Jefferson University Hospital. MBAT integrates known benefits of art therapy, group therapy, and mindfulness-based stress reduction. Each of these fundamentally different modalities has documented usefulness in the treatment of cancer patients. The multi-modal approach is designed to enhance both the supportive and expressive aspects of the group experience. The study will be done with 96 patients who have a variety of cancer types. Participants will be matched for age and assigned randomly to either the MBAT experimental group or a non-intervention control group. Both groups will continue to receive their usual oncologic/medical care. The MBAT program consists of eight weekly meetings of two and one half-hours in length. At the end of the eight weeks, participants in the control group will be crossed over to the experimental intervention arm for an additional eight weeks. Participants will be assessed pre- and post-intervention on measures of health-related quality of life, psychological distress, and coping, using standardized outcome instruments (SF-36, SCL-90-R and COPE). Our long-term goal is to collect sufficient data to determine the overall efficacy of this promising intervention and to identify which patients are particularly likely to benefit from MBAT.
The present invention relates to a formulation for beautifying faces and removing spots. The present invention is characterized in that the formulation is prepared by mixing 5 to 8 portions of Chinese angelica roots, 1 to 3 portions of safflower, 1 to 3 portions of pearl fine powder, 4 to 7 portions of roxburgh rose powder and 0.5 to 2 portions of vitamin E powder. A preparation method of the formulation is characterized in that after cleaned, roxburgh rose fruits are squeezed to obtain fruit juice; the fruit juice is immediately dried by freezing or spraying to obtain freeze-drying powder or spray-drying powder which are mixed with the Chinese angelica roots, the safflower, pearls ground into fine powder and the vitamin E powder proportionally, and then a solid oral preparation is obtained. The roxburgh rose powder, the Chinese angelica root powder and the safflower powder are 80 to 100 meshes, and the pearl powder is 1000 meshes. The standing time of the roxburgh rose fruit juice is at most 12 hours for freeze drying. The freeze-drying temperature is controlled to be-50 to 40 DEG C. The vacuum degree is 5 to 50 pa, and the time is 3 to 35 hours.
FIELD: veterinary science, cattle breeding. SUBSTANCE: invention proposes an aqueous solution of α-propylene glycol administrated to calves in colostrum at the second feeding. For treatment of mastitis cows 6-8 ml of 10% solution is administrated by intracisternal route and 15 ml of 10% solution is administrated by intrauterine route for treatment of cows with endometritis. The preparation stimulates the natural resistance of body, enhances the protective function of gastroenteric tract and uterine mucosa, suppresses an opportunistic microflora that provides prophylaxis and effective therapy of sicknesses and increase of animal productivity. The preparation provides an immunostimulation and prophylaxis of gastroenteric sicknesses in calves and used for treatment of cows with mastitis and endometritis. EFFECT: enhanced effectiveness of an agent. 5 ex
Post-stroke depression (POSD) is a common difficulty and most predominant emotional syndrome after stroke often consequences in poor outcomes. In the present investigation, we have designed and studied the neurologically active celastrol/minocycline encapsulated with macrophages-derived exosomes functionalized PLGA nanoformulations (CMC-EXPL) to achieve enhanced anti-inflammatory behaviour and anti-depressant like activity in a Rat model of POSD. The animal model of POSD was established through stimulating process with chronic unpredictable mild stress (CUM) stimulations after procedure of middle cerebral artery occlusion (MCAO). Neuronal functions and Anti-inflammation behaviours were observed by histopathological (H&E) examination and Elisa analyses, respectively. The anti-depressive activity of the nanoformulations treated Rat models were evaluated by open-field and sucrose preference test methods. Microglial polarization was evaluated via flow-cytometry and qRT-PCR observations. The observed results exhibited that prepared nanoformulations reduced the POSD-stimulated depressive-like activities in rat models as well alleviated the neuronal damages and inflammatory responses in the cerebral hippocampus. Importantly, prepared CMC-EXPL nanoformulation effectively prevented the M1 pro-inflammatory polarization and indorsed M2 anti-inflammatory polarization, which indicates iNOS and CD86 levels significantly decreased and upsurged Arg-1 and CD206 levels. CMC-EXPL nanoformulation suggestively augmented anti-depressive activities and functional capability and also alleviated brain inflammation in POSD rats, demonstrating its therapeutic potential for POSD therapy.
The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.
Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
BACKGROUND: Public health surveillance is vital for monitoring and controlling disease spread. In the Philippines, an effective surveillance system is crucial for managing diverse infectious diseases. The Newcomb-Benford Law (NBL) is a statistical tool known for anomaly detection in various datasets, including those in public health.
METHODS: Using Philippine epidemiological data from 2019 to 2023, this study applied NBL analysis. Diseases included acute flaccid paralysis, diphtheria, measles, rubella, neonatal tetanus, pertussis, chikungunya, dengue, leptospirosis and others. The analysis involved Chi-square tests, Mantissa Arc tests, Mean Absolute Deviation (MAD) and Distortion Factor calculations.
RESULTS: Most diseases exhibited nonconformity to NBL, except for measles. MAD consistently indicated nonconformity, highlighting potential anomalies. Rabies consistently showed substantial deviations, while leptospirosis exhibited closer alignment, especially in 2021. Annual variations in disease deviations were notable, with acute meningitis encephalitis syndrome in 2019 and influenza-like illness in 2023 having the highest deviations.
CONCLUSIONS: The study provides practical insights for improving Philippine public health surveillance. Despite some diseases showing conformity, deviations suggest data quality issues. Enhancing the PIDSR, especially in diseases with consistent nonconformity, is crucial for accurate monitoring and response. The NBL's versatility across diverse domains emphasizes its utility for ensuring data integrity and quality assurance.
PURPOSE:To obtain hybridoma by fusion of a spleen cell of mammal which is immobilized with human fibronectin with a myeloma cell and produce the titled novel antibody having apparent binding domain from the resultant hybridoma. CONSTITUTION:Human fibronectin is injected into a mammal such as mouse to immobilize the mammal and a spleen cell obtained from the above-mentioned mammal is fused with a myeloma cell by action of polyethylene glycol. The fused cell is cultivated and the resultant cell is subjected to cloning to provide fibronectin monoclonal antibody-producing hybridoma, which is then cultivated and supernatant of the cultivated hybridoma is subjected to salting, etc., to afford an antibody fraction. The resultant antibody fraction is combined with a domain having 22,000mol.wt., a domain having 24,000mol.wt. and a domain, etc., having 105,000mol.wt. which are obtained by cleaving the human hybronectin with thermolysin.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention describes novel substituted derivatives of piperidine of the general formula (I)   where R 1  means benzothienyl or thienyl substituted with C 1-6 -alkyl; R 2  means phenyl substituted with halogen atom; R 3  means   or   where R 4  and R 5  in common with N atom to which they are bound form 4-, 5- or 6-membered heterocyclic group; X means a bond or phenyl; R 6  means hydrogen atom or C 1-6 -alkyl; R 7  means C 3-6 -cycloalkyl or phenyl that can be substituted possibly with C 1-6 -alkyl; m is a whole number 1, 2, 3 or 4. Invention relates also to their pharmaceutically acceptable salts or solvates and pharmaceutical composition based on thereof. These compounds show neuroleptic effect and can be used in treatment of patients with psychotic disorders. EFFECT: valuable medicinal properties of compounds. 4 cl, 2 tbl